Hubbry Logo
BrimonidineBrimonidineMain
Open search
Brimonidine
Community hub
Brimonidine
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Brimonidine
Brimonidine
Brimonidine
View on Wikipedia
from Wikipedia

Brimonidine
Clinical data
Pronunciation/brɪˈmoʊnɪdiːn/ bri-MOH-nid-een
Trade namesAlphagan, Mirvaso, Lumify, others
AHFS/Drugs.comMonograph
MedlinePlusa601232
License data
Pregnancy
category
  • AU: B3
Routes of
administration		Topical
ATC code
Legal status
Legal status
Pharmacokinetic data
MetabolismPrimarily liver
Elimination half-life3 hours (ocular), 12 hours (topical)
Identifiers
  • 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl) quinoxalin-6-amine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.149.042 Edit this at Wikidata
Chemical and physical data
FormulaC11H10BrN5
Molar mass292.140 g·mol−1
3D model (JSmol)
Melting point252 °C (486 °F)
  • Brc2c1nccnc1ccc2N/C3=N/CCN3
  • InChI=1S/C11H10BrN5/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8/h1-4H,5-6H2,(H2,15,16,17) checkY
  • Key:XYLJNLCSTIOKRM-UHFFFAOYSA-N checkY
  (verify)

Brimonidine is an α2 agonist medication used to treat open-angle glaucoma, ocular hypertension, and rosacea.[5][6] In rosacea it improves the redness.[6] It is used as eye drops or applied to the skin.[5][6] It is also available in the fixed-dose combination medication brimonidine/timolol along with timolol maleate.[7]

Common side effects when used in the eyes include itchiness, redness, and a dry mouth.[5] Common side effects when used on the skin include redness, burning, and headaches.[6] More significant side effects may include allergic reactions and low blood pressure.[6][5] Use in pregnancy appears to be safe.[6][5] When applied to the eye it works by decreasing the amount of aqueous humor made while increasing the amount that drains from the eye.[5] When applied to the skin it works by causing blood vessels to contract.[6]

Brimonidine was patented in 1972 and came into medical use in 1996.[8] It is available as a generic medication.[9][10] In 2023, it was the 213th most commonly prescribed medication in the United States, with more than 2 million prescriptions.[11][12]

Medical uses

[edit]

Brimonidine is indicated for the lowering of intraocular pressure in people with open-angle glaucoma or ocular hypertension.[2] It is also used to reduce redness of the eye.[4] The gel is indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older.[3]

A 2017 Cochrane review found insufficient evidence to determine if brimonidine slows optic nerve damage.[13]

Mechanism of action

[edit]

Brimonidine is an α2 adrenergic agonist.[5]

Peripheral α2 agonist activity results in vasoconstriction of blood vessels (as opposed to central α2 agonist activity that decreases sympathetic tone, as can be seen by the medication clonidine). This vasoconstriction may explain the acute reduction in aqueous humor flow. The increased uveoscleral outflow from prolonged use may be explained by increased prostaglandin release due to α adrenergic stimulation. This may lead to relaxed ciliary muscle and increased uveoscleral outflow.[14]

Society and culture

[edit]

Names

[edit]

It is sold under the brand names Alphagan, Alphagan-P, Mirvaso, Lumify, Brymont, and others.

References

[edit]

Further reading

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Brimonidine

View on Grokipedia
from Grokipedia
Brimonidine is a selective administered primarily as an ophthalmic solution to reduce elevated in patients with open-angle or . It is also available as a topical for the treatment of persistent (nontransient) facial associated with in adults. In its ophthalmic form, brimonidine lowers through a dual mechanism: it decreases the production of aqueous humor by the and enhances uveoscleral outflow, with peak hypotensive effects occurring approximately two hours after administration. For rosacea, the topical acts as a vasoconstrictor on small arterioles in the skin, rapidly reducing redness by targeting s without significantly affecting other vascular beds. The drug was first approved by the U.S. in 1996 for ophthalmic use under the brand name Alphagan, with a lower-concentration (0.15%) approved in 2001 to minimize systemic absorption; the topical (Mirvaso, 0.33%) received approval in 2013 as the first dedicated treatment for . Common adverse effects of ophthalmic brimonidine include ocular hyperemia, burning or stinging upon instillation, , and systemic issues such as dry mouth, fatigue, and headache due to potential absorption. With the topical gel, side effects often involve worsening (), flushing, pruritus, and skin irritation, particularly if over-applied. Brimonidine is contraindicated in infants under two years due to risks of apnea and , and caution is advised in patients with or those using monoamine oxidase inhibitors. Overall, its favorable selectivity for alpha-2 receptors over alpha-1 helps limit cardiovascular side effects compared to earlier agents like .

Medical uses

Glaucoma and ocular hypertension

Brimonidine , formulated at concentrations of 0.1% to 0.2%, serve as a primary treatment for lowering elevated (IOP) in patients with open-angle or . As monotherapy, brimonidine effectively reduces IOP by decreasing aqueous humor production and enhancing uveoscleral outflow, making it suitable for initial therapy in these conditions. It is also employed as adjunctive therapy alongside other ocular hypotensives when additional IOP control is needed, offering flexibility in management strategies. The standard dosing involves instilling one drop into the affected eye(s) three times daily, spaced approximately 8 hours apart, to maintain consistent IOP reduction. begins within 1 hour of administration, with peak hypotensive effects achieved at 2 hours and sustained for up to 12 hours, aligning well with the dosing schedule for thrice-daily use. This pharmacokinetic profile supports its role in preventing diurnal IOP fluctuations, a key factor in progression. Clinical is well-established, with brimonidine typically reducing IOP by 20-25% from baseline in most patients, as demonstrated in pivotal trials comparing it to timolol. For instance, monotherapy with 0.2% brimonidine achieved mean IOP reductions of approximately 20.2%, while long-term studies confirm sustained control over 12 months without significant in the majority of cases. In scenarios, with timolol—such as in the fixed-dose product Combigan (0.2% brimonidine /0.5% timolol maleate)—provides additive IOP lowering of up to 30-35%, superior to either agent alone, and improves adherence through simplified dosing. Brimonidine is often selected for patients intolerant to beta-blockers, as it lacks cardiopulmonary contraindications like or , or those unable to use analogs due to side effects such as growth or periocular pigmentation. This positions brimonidine as a valuable alternative in personalized regimens, particularly for elderly or comorbid populations.

Ocular hyperemia

Brimonidine tartrate ophthalmic solution 0.025% is indicated for the temporary relief of redness of the eye due to minor irritations. The recommended dose is one drop in the affected eye(s), applied up to four times daily, as needed. This low-concentration formulation acts as a selective alpha-2 adrenergic agonist to constrict ocular blood vessels, reducing hyperemia with onset within 1 minute and effects lasting up to 8 hours. It is available over-the-counter under brand names such as Lumify and is not intended for treatment of glaucoma or other serious eye conditions. Generics received FDA approval as early as 2024.

Rosacea

Brimonidine is available as a 0.33% topical gel (brimonidine tartrate), marketed under the brand name Mirvaso, for the topical treatment of persistent (nontransient) facial associated with in adults aged 18 years and older. The gel is applied once daily as a pea-sized amount (approximately 1 gram) in a thin layer to the central forehead, chin, nose, each cheek, and other affected areas of the face, while avoiding the eyes, mouth, and mucous membranes; hands should be washed immediately after application. In the context of , brimonidine acts as a selective , inducing of superficial dermal blood vessels to reduce facial redness. This vasoconstrictive effect leads to a visible reduction in within 30 minutes of application, with peak efficacy typically occurring at 3 to 6 hours and lasting up to 12 hours before symptoms gradually return. Two pivotal phase 3, randomized, double-blind, vehicle-controlled clinical trials (n=553) demonstrated the of brimonidine 0.33% for moderate to severe persistent in . In these studies, significantly more achieved at least a 1-grade improvement in both assessment (CEA) and (PSA) scores compared to vehicle on day 29, with success rates of approximately 58% to 71% for brimonidine versus 29% to 43% for vehicle at various time points up to 12 hours post-application (p<0.001). Composite success, defined as a 2-grade improvement in both CEA and PSA, was achieved by 22% to 31% of brimonidine-treated versus 9% to 11% with vehicle at 3 and 12 hours on day 29. These trials confirmed rapid onset on day 1, with about 28% of showing 1-grade improvement at 30 minutes versus 7% with vehicle (p<0.001). Brimonidine is specifically indicated for erythematotelangiectatic to address persistent redness but does not treat inflammatory lesions such as papules or pustules, telangiectasia, or phymatous changes. The treatment is suitable for adults with moderate to severe facial erythema but is not recommended for ocular rosacea or patients under 18 years. Discontinuation may lead to rebound erythema, where redness worsens beyond baseline in some patients (reported in up to 9% in long-term studies), typically resolving within 4 to 24 hours after stopping use. A 12-month open-label extension study supported sustained efficacy and tolerability with once-daily use in up to 71% of patients maintaining improvement over time.

Pharmacology

Mechanism of action

Brimonidine is a selective α₂-adrenergic receptor agonist that primarily exerts its therapeutic effects by binding to and activating α₂ receptors, with a selectivity ratio of up to 1780-fold for α₂ over α₁ receptors. This high selectivity distinguishes it from less selective agents like apraclonidine, which exhibits only about 23- to 30-fold preference for α₂ receptors and greater α₁ activity, potentially leading to unwanted effects such as mydriasis. Brimonidine demonstrates potent binding affinity to the α₂A subtype and minimal interaction with α₁ receptors, minimizing pupillary dilation. In the treatment of glaucoma and ocular hypertension, brimonidine lowers intraocular pressure (IOP) through a dual mechanism involving reduced aqueous humor production and enhanced outflow. It activates postsynaptic α₂ receptors on the non-pigmented ciliary epithelial cells, inhibiting adenylate cyclase activity and thereby decreasing cyclic AMP levels, which suppresses the secretion of aqueous humor. Additionally, brimonidine stimulates presynaptic α₂ autoreceptors on sympathetic nerve terminals in the ciliary body, reducing norepinephrine release and further attenuating the sympathetic stimulation of aqueous production. Chronic administration shifts the predominant effect toward increasing uveoscleral outflow by relaxing the trabecular meshwork and ciliary muscle via α₂ receptor activation, facilitating alternative drainage pathways for aqueous humor. For rosacea, brimonidine's mechanism centers on its action in the skin, where it binds to α₂ receptors on vascular smooth muscle cells in dermal arterioles and venules, inducing direct vasoconstriction. This reduces blood flow to superficial capillaries, alleviating persistent facial erythema by counteracting the vasodilation characteristic of the condition. Compared to clonidine, another α₂ agonist, brimonidine is less lipophilic, which limits systemic absorption while maintaining effective ocular and topical penetration.

Pharmacokinetics

Brimonidine is rapidly absorbed following ophthalmic administration, with peak plasma concentrations typically occurring within 0.5 to 4 hours after instillation of a 0.1% or 0.2% solution. Systemic bioavailability is low due to the corneal barrier and nasolacrimal drainage, resulting in plasma concentrations of approximately 0.06 ng/mL after multiple dosing. For the topical gel formulation used in rosacea (0.33%), absorption is also rapid, with mean peak plasma concentrations of 46 pg/mL and minimal systemic exposure, as area under the curve values were 417 pg·hr/mL after repeated application, showing no accumulation. Following absorption, brimonidine demonstrates good penetration into ocular tissues, achieving maximum concentrations in the aqueous humor of 2.6 to 3.1 ng/mL after dosing with 0.1% to 0.15% ophthalmic solutions. Its lipophilicity (logP ≈ 1.3) facilitates this distribution while limiting extensive systemic spread. Brimonidine crosses the blood-brain barrier to a limited extent, contributing to occasional central nervous system effects at higher exposures. Brimonidine undergoes extensive hepatic metabolism, primarily via aldehyde oxidase to inactive metabolites such as 2-carboxybrimonidine, with first-pass metabolism further reducing systemic levels after absorption. Elimination of brimonidine is primarily renal, with approximately 87% of an orally administered dose eliminated within 120 hours, about 74% recovered in urine; systemic half-life ranges from 2 to 3 hours, and clearance is estimated at around 378 mL/min. The majority is excreted as metabolites, with low amounts of unchanged drug in urine. In special populations, clearance is reduced in hepatic impairment due to predominant liver metabolism, necessitating dose adjustments or caution. No clinically significant differences in pharmacokinetics occur with age or gender, though neonates and infants require careful monitoring owing to risks of apnea from even low systemic exposure.

Adverse effects

Ocular effects

Brimonidine ophthalmic solution commonly causes localized ocular adverse effects, with the most frequent being conjunctival hyperemia, eye pruritus, and allergic conjunctivitis, each occurring in 10-20% of patients in clinical trials. Other common effects (>10% incidence in some studies) include burning or stinging upon instillation and sensation. Blurred vision, often due to transient changes in accommodation, is also reported, typically in 10-30% of users. Allergic reactions to brimonidine manifest as , follicular , and , affecting 10-20% of long-term users; these symptoms usually resolve upon discontinuation of the drug. In clinical trials, approximately 20% of patients discontinued treatment due to ocular , with incidence rates ranging from 10.5% to 25.7% depending on the study population and duration. Formulations with less irritating preservatives, such as 0.1% or 0.15% Alphagan P (preserved with Purite), reduce irritation and allergic responses compared to (BAK)-preserved versions, with lower discontinuation rates (21.4% vs. 33.5%) and improved tolerability. Preservative-free brimonidine formulations, approved in recent years, further reduce ocular surface irritation and improve patient satisfaction as of 2023. Long-term use of brimonidine may lead to rare reports of corneal erosion or superficial punctate , particularly with BAK-preserved formulations, and can exacerbate dry eye symptoms through chronic ocular surface disruption. Management strategies include dose reduction to minimize exposure or switching to alternative agents such as latanoprost, which has a different tolerability profile.

Systemic effects

Brimonidine, when administered ophthalmically, can lead to systemic effects due to low but measurable absorption into the bloodstream. Common systemic adverse reactions occurring in 10-30% of patients using the 0.2% formulation and 5-9% with 0.15% Alphagan P include dry mouth (), fatigue, drowsiness, and . These effects stem from brimonidine's alpha-2 activity, which can influence and autonomic functions beyond the eye. In pediatric patients, particularly those with , systemic effects are more pronounced and frequent, affecting up to 80% in some studies, with or reported in 50-83% of children aged 2-6 years per FDA data. Infants under 2 years face a heightened risk of serious complications, including apnea, , , and unresponsiveness, leading to contraindication in this age group. Neurological manifestations like and may impair alertness, warranting avoidance in children or adults operating machinery or engaging in activities requiring full cognitive function. Cardiovascular effects are generally mild but can include or , particularly in susceptible individuals with preexisting conditions; occurs rarely. These arise from systemic alpha-2 reducing sympathetic outflow, though clinical trials show minimal changes in most adults. For the topical formulation used in treatment, systemic absorption is minimal, resulting in low risk of widespread effects, though has been reported in about 4% of patients in long-term studies. Possible related issues include rebound flushing upon discontinuation, but these are primarily local rather than systemic. Monitoring recommendations include periodic checks, especially in elderly patients or those with , to detect any hypotensive trends early. The low systemic of brimonidine contributes to the relative infrequency of severe effects in adults.

Safety considerations

Contraindications

Brimonidine tartrate ophthalmic solution is contraindicated in patients with a known to brimonidine or any component of the formulation, as severe allergic reactions may occur upon exposure. It is also contraindicated in neonates and premature infants due to the high risk of profound , , , , and apnea associated with systemic absorption. Relative contraindications include severe , such as uncontrolled or recent , where brimonidine's alpha-2 effects could worsen hemodynamic instability. Use with caution in patients with hepatic impairment, as the drug undergoes extensive hepatic metabolism but has not been specifically studied in this population, potentially leading to altered and increased systemic exposure. Similarly, use with caution in individuals with a due to the risk of vascular insufficiency from its effects. There are no adequate and well-controlled studies of brimonidine in women. It should be used during pregnancy only if the potential benefit justifies the potential risk to the . During , brimonidine is not recommended, as it may be excreted in and cause or apnea in infants; a decision should be made to discontinue or the drug. For pediatric patients, brimonidine is contraindicated in those under 2 years of age; in children aged 2 to 12 years, it may be used with caution and close monitoring for systemic adverse effects due to higher absorption risks compared to adults.

Topical Gel ()

MIRVASO (brimonidine) topical gel is contraindicated in patients with known to brimonidine or any component of the formulation. There are no adequate and well-controlled studies in pregnant women; use only if potential benefit justifies potential risk. It is not known if excreted in human milk; consider risks to vs. benefit to . No specific pediatric contraindications, but risk of serious adverse reactions from accidental ingestion in children; keep out of reach.

Drug interactions

Brimonidine, when used topically in the eye, can exhibit additive systemic effects with other alpha-2 adrenergic agonists such as , potentially enhancing and due to shared mechanisms of action. Similarly, concomitant use with (CNS) depressants, including alcohol, barbiturates, opiates, sedatives, or anesthetics, may potentiate CNS depression, leading to increased drowsiness or respiratory effects from systemic absorption. In patients receiving antihypertensive medications, brimonidine may further lower , necessitating caution; this includes beta-blockers like timolol, where fixed combinations such as Combigan require monitoring for enhanced or , particularly in the initial treatment period. may also contribute to additive cardiovascular depression when combined with brimonidine. Brimonidine undergoes extensive hepatic primarily via aldehyde oxidase, and while specific metabolic interactions are limited, caution is advised with (MAO) inhibitors, as they may interfere with amine , potentially increasing systemic exposure and risks such as . antidepressants can blunt brimonidine's hypotensive effects by altering amine uptake and . No significant pharmacokinetic or pharmacodynamic interactions have been reported with prostaglandin analogs (e.g., latanoprost) or carbonic anhydrase inhibitors (e.g., ), allowing safe concomitant use for additive reduction in management.

Topical Gel ()

Similar interactions as ophthalmic: additive effects with antihypertensives, CNS depressants, and MAO inhibitors, potentially enhancing or . Use caution in patients with severe or on blood pressure-lowering therapies.

Chemistry

Molecular structure

Brimonidine is a synthetic belonging to the class of alpha-2 adrenergic agonists, characterized by its core structure substituted with key functional groups that confer selectivity for alpha-2 receptors. The molecule features a bicyclic , which consists of a ring fused to a ring, with a atom at the 5-position and an group at the 6-position linked to a 4,5-dihydro-1H-imidazol-2-yl moiety. This ring attached via the nitrogen is the primary responsible for binding to alpha-2 adrenergic receptors, enhancing the compound's selectivity compared to earlier analogs. The of brimonidine is C11H10BrN5, with a molecular weight of 292.13 g/mol. In clinical formulations, it is predominantly used as the , which has the formula C11H10BrN5 • C4H6O6 (or C15H16BrN5O6) and a molecular weight of 442.22 g/mol, improving its solubility and stability for ophthalmic applications. The IUPAC name for brimonidine is 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine, reflecting the precise positioning of substituents on the core. Structurally, brimonidine is derived from , an earlier imidazoline-based alpha-2 , but incorporates a ring in place of clonidine's simpler phenyl-imidazoline scaffold, along with a , which contributes to its improved receptor selectivity (approximately 1000-fold greater for alpha-2 over alpha-1 receptors). This modification reduces systemic side effects while maintaining potent ocular hypotensive activity. The molecule lacks chiral centers, rendering it achiral with no stereoisomers of pharmacological relevance in its standard form.

Physical and chemical properties

Brimonidine is an off-white to yellow to pink powder. It has a in the range of 202–210°C. The compound exhibits good solubility as the salt, with approximately 34 mg/mL in at , which facilitates its use in ophthalmic formulations. It is moderately lipophilic, with a logP value of 1.37, supporting adequate corneal penetration for topical ocular delivery. Brimonidine has two pKa values: 7.78 for the moiety and 4.27 for the group, influencing its ionization and solubility profile across physiological ranges. Brimonidine is sensitive to , requiring protection during storage, and to oxidative conditions, as demonstrated by degradation under forced oxidation stress studies. It remains stable in aqueous solutions within a range of 6–8, where the salt enhances overall and formulation viability for ophthalmic use. In commercial eye drop formulations, it is typically preserved with 0.005% and adjusted to a of 7.4–7.7 to ensure ocular compatibility and stability.

History

Development

Brimonidine was developed in the late 1980s by as a highly selective intended to lower (IOP) in patients while minimizing the side effects associated with earlier agents like , which exhibited significant alpha-1 adrenergic activity leading to issues such as and allergic reactions. This selectivity was achieved through structural modifications centered on a bromo- core, which enhanced binding affinity to alpha-2 receptors over alpha-1 subtypes, as demonstrated in early receptor binding assays. The compound, chemically known as 5-bromo-6-(2-imidazolin-2-ylamino)quinoxaline tartrate, was synthesized starting from 5-bromo-6-aminoquinoxaline intermediates to optimize pharmacological specificity. In preclinical studies conducted during the early , brimonidine demonstrated robust IOP-lowering effects in animal models, including rabbits and monkeys, by reducing aqueous humor production and increasing uveoscleral outflow without inducing pupillary dilation, unlike non-selective alpha agonists. Topical application in rabbits resulted in dose-dependent IOP reductions of up to 30-40% lasting 8-12 hours, mediated primarily through ocular alpha-2 receptors, while in monkeys, both ocular and imidazoline sites contributed to contralateral eye effects. Notably, these models showed minimal over repeated dosing compared to non-selective agents, with sustained efficacy observed for up to 4 weeks, supporting its potential for chronic therapy. Phase 3 clinical trials in the mid-1990s involving patients with open-angle and confirmed brimonidine's efficacy as a twice-daily 0.2% ophthalmic solution, achieving mean IOP reductions of approximately 20-25% from baseline over 6-12 months, comparable to timolol but with a different mechanism enhancing outflow. These multicenter, randomized, double-masked studies enrolled over 1,000 participants and demonstrated additive benefits when combined with beta-blockers, with peak effects occurring 1-2 hours post-dosing and trough reductions maintained at 12 hours. An extension study published in 2001 evaluated brimonidine in pediatric patients aged 2-12 years, reporting IOP reductions of 15-20% but identifying heightened risks, including and in up to 50% of younger children under 6 years, leading to recommendations for cautious use or avoidance in infants. In the , brimonidine was repurposed for dermatological applications, leveraging its vasoconstrictive properties to target facial in . Phase 2 trials conducted between 2008 and 2010 tested topical formulations at concentrations of 0.1-0.5%, showing rapid onset of erythema reduction within 30 minutes and sustained effects up to 12 hours in patients with moderate-to-severe rosacea, with success rates (defined as ≥2-grade improvement on the Clinician Erythema Assessment) reaching 60-70% versus 20-30% for vehicle. These dose-ranging studies, involving around 200 participants each, informed the development of a 0.33% gel optimized for once-daily application, demonstrating improved tolerability over higher strengths while maintaining vasoconstrictor efficacy through alpha-2 mediated reduction in dermal blood flow.

Regulatory approvals

Brimonidine tartrate ophthalmic solution 0.2% (Alphagan) was approved by the U.S. Food and Drug Administration (FDA) on September 6, 1996, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In 2001, the FDA approved its use in pediatric patients aged 2 years and older for the same indications. The over-the-counter formulation Lumify (brimonidine tartrate 0.025% ophthalmic solution) received FDA approval on December 22, 2017, for the temporary relief of redness of the eye due to minor irritations. In April 2024, the FDA approved a preservative-free version of Lumify. In August 2024, the FDA approved a generic version of brimonidine tartrate ophthalmic solution 0.1% by Lupin Limited. Also in August 2024, Lupin received tentative approval for a generic brimonidine tartrate ophthalmic solution 0.025% (OTC). In the , brimonidine tartrate 0.2% solution was first approved on March 18, 1997, via the national authorization procedure in the , for the reduction of in patients with open-angle or . The topical gel formulation Mirvaso (brimonidine 0.33%) was approved by the FDA on August 23, 2013, for the topical treatment of persistent facial associated with in adults, and received marketing authorization on February 26, 2014, for the symptomatic treatment of facial of in adult patients. Brimonidine tartrate was approved in in 1997 for the control of intraocular pressure in patients with open-angle or . Generic versions of brimonidine tartrate ophthalmic solutions became available following the expiration of patents on the original branded product in the mid-2000s. The FDA prescribing information includes a contraindication against use in pediatric patients younger than 2 years due to postmarketing reports of apnea, , , and , with symptoms of brimonidine overdose reported in this age group. No major withdrawals or controversies have been associated with brimonidine, though supply disruptions have occasionally occurred due to manufacturing challenges, resolved through alternative suppliers including generics.

Society and culture

Brand names

Brimonidine is marketed under several proprietary brand names worldwide, primarily as ophthalmic solutions for and , over-the-counter redness relief drops, combination therapies, and a topical gel for . In the United States, the primary brand for prescription ophthalmic drops is Alphagan (developed by , now part of ), available in concentrations of 0.2%, 0.15%, and 0.1% brimonidine . A variant, Alphagan P, uses Purite (sodium chlorite) as a that breaks down into natural tear components, in contrast to the benzalkonium chloride (BAK)-preserved original Alphagan formulation. For over-the-counter use, Lumify () offers a 0.025% brimonidine solution specifically for ocular redness relief. Generic equivalents, such as Brimonidine Tartrate Ophthalmic Solution in 0.1%, 0.15%, and 0.2% strengths, are widely available from manufacturers including , , and . Combination products pair brimonidine with other agents to enhance reduction. Combigan (/) combines 0.2% brimonidine tartrate with 0.5% timolol maleate as an ophthalmic solution. Simbrinza () is a suspension of 0.2% brimonidine tartrate and 1% brinzolamide. These fixed-dose combinations are prescribed for patients requiring multiple therapies. For dermatological use, Mirvaso () is a 0.33% brimonidine tartrate topical gel approved for persistent facial associated with . Internationally, brand names vary by region; in , examples include Alphagan () and generic brimonidine tartrate , while in Asia (e.g., and ), brands such as Brimochek (Micro Labs), Brimo Eye (), and Alphagan () are common, alongside numerous generics like Albrim-LS and Brent-LS. Over 50 generic formulations of brimonidine tartrate are available globally, reflecting its established use and patent expirations.

Availability

Brimonidine is available by prescription for the treatment of and , as well as for persistent facial associated with in adults. A low-dose (0.025% ophthalmic solution, marketed as Lumify) is approved for over-the-counter use to relieve ocular redness due to minor irritations, having been made available without a prescription since 2017. Generic versions of brimonidine have been widely available since the patent expiration of the original Alphagan (0.2% solution) around 2010, with FDA approval for generics of Alphagan P (0.15% and 0.1% formulations) following in subsequent years, including recent approvals enabling broader market entry by 2024. In the United States, monthly costs for generic brimonidine typically range from $10 to $50, depending on dosage and pharmacy, while prices are lower in and , often $5 to $15 per month due to international sourcing and generic competition. The drug is distributed in over 100 countries worldwide, supported by its approval in major markets including the , nations, , , and , with import/export activity spanning dozens of additional regions. Occasional shortages have been reported, particularly in developing regions like parts of the and , attributed to supply chain disruptions, commercial viability issues, and limited local manufacturing. In October 2025, Apotex recalled certain lots of brimonidine/timolol ophthalmic solution due to potential lack of sterility, affecting supply of product. In the United States, prescription brimonidine for glaucoma is covered by 100% of Medicare Part D plans and most private insurance, often with low copays after deductibles, while coverage for rosacea formulations like Mirvaso typically requires prior authorization and may be more restricted. Over-the-counter versions such as Lumify are not covered by insurance and must be purchased out-of-pocket. Generics of the brimonidine tartrate 0.33% gel for rosacea (equivalent to Mirvaso) were first approved by the FDA in 2021, facilitating emerging biosimilar options and potentially improving access and affordability for topical rosacea treatments.

References

  1. https://go.drugbank.com/drugs/DB00484
  2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204708s005lbl.pdf
  3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020613s031lbl.pdf
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC1936355/
  5. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021770s014%2C021262s028lbl.pdf
  6. https://pi.bausch.com/globalassets/pdf/PackageInserts/Pharma/Rx-Generics/Brimonidine-Tartrate-Ophthalmic-Solution.pdf
  7. https://www.sciencedirect.com/science/article/abs/pii/S0149291800879771
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC3699296/
  9. https://www.tandfonline.com/doi/full/10.2147/tcrm.s24337
  10. https://pubmed.ncbi.nlm.nih.gov/12069372/
  11. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208743s000lbl.pdf
  12. https://www.lupin.com/US/media/lupin-receives-tentative-approval-from-u-s-fda-for-brimonidine-tartrate-ophthalmic-solution-0-025-otc
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC5505675/
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC4627400/
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC6592871/
  16. https://pubmed.ncbi.nlm.nih.gov/7487618/
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC10969194/
  18. https://pubmed.ncbi.nlm.nih.gov/9534022/
  19. https://pdf.hres.ca/dpd_pm/00000375.PDF
  20. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204708lbl.pdf
  21. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021770s000_PharmR.pdf
  22. https://pubchem.ncbi.nlm.nih.gov/compound/Brimonidine
  23. https://pubmed.ncbi.nlm.nih.gov/8905918/
  24. https://pubmed.ncbi.nlm.nih.gov/20367525/
  25. https://pubmed.ncbi.nlm.nih.gov/10334342/
  26. https://www.sciencedirect.com/science/article/abs/pii/S0008418202800941
  27. https://www.nature.com/articles/s41598-023-31726-1
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC9437175/
  29. https://www.singlecare.com/blog/latanoprost-alternatives/
  30. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021770s014,021262s028lbl.pdf
  31. https://pubmed.ncbi.nlm.nih.gov/16225927/
  32. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5316cf97-e38e-4e78-aff2-c6972a666f3d&type=display
  33. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=feaf1480-a4b8-4486-992a-96be3a596243
  34. https://pubmed.ncbi.nlm.nih.gov/8970244/
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC7859663/
  36. https://pubchem.ncbi.nlm.nih.gov/compound/Brimonidine-tartrate
  37. https://www.sciencedirect.com/topics/medicine-and-dentistry/brimonidine
  38. https://pdf.hres.ca/dpd_pm/00027980.PDF
  39. https://go.drugbank.com/salts/DBSALT000195
  40. https://pdf.hres.ca/dpd_pm/00072258.PDF
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC5505891/
  42. http://yxsj.smmu.edu.cn/en/article/id/20080516
  43. https://www.rxabbvie.com/pdf/alphagan_pi.pdf
  44. https://pubmed.ncbi.nlm.nih.gov/11249518/
  45. https://pubs.acs.org/doi/10.1021/acs.oprd.4c00280
  46. https://patents.google.com/patent/CN101318939A/en
  47. https://pubmed.ncbi.nlm.nih.gov/8744846/
  48. https://pubmed.ncbi.nlm.nih.gov/8970245/
  49. https://pubmed.ncbi.nlm.nih.gov/11641636/
  50. https://pubmed.ncbi.nlm.nih.gov/23839181/
  51. https://www.federalregister.gov/documents/2003/06/11/03-14680/determination-that-brimonidine-tartrate-ophthalmic-solution-02-was-not-withdrawn-from-sale-for
  52. https://www.fda.gov/files/drugs/published/228_208144-brimonidine-CDTL-clinical-prea.pdf
  53. https://www.drugs.com/history/lumify.html
  54. https://ir.bausch.com/press-releases/bausch-lomb-launches-new-lumifyr-preservative-free-redness-reliever-eye-drops-united
  55. https://www.lupin.com/US/media/lupin-receives-approval-from-u-s-fda-for-brimonidine-tartrate-ophthalmic-solution-0-1
  56. https://www.ema.europa.eu/en/documents/assessment-report/simbrinza-epar-public-assessment-report_en.pdf
  57. https://www.drugs.com/history/mirvaso.html
  58. https://www.prnewswire.com/news-releases/mirvaso-brimonidine-the-first-and-only-treatment-targeting-the-facial-redness-of-rosacea-approved-by-the-european-commission-247197631.html
  59. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notices-changes/consultation-brimonidine.html
  60. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=125699
  61. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=264c4494-c225-486f-888a-caaf36be46b3&version=24
  62. https://www.alphaganp.com/
  63. https://www.alphaganp.com/patient/why-alphagan
  64. https://www.drugs.com/ingredient/brimonidine.html
  65. https://www.medicines.org.uk/emc/ingredient/2510
  66. https://www.mims.com/india/drug/info/brimonidine
  67. https://www.drugpatentwatch.com/p/generic-api/BRIMONIDINE%2BTARTRATE
  68. https://www.goodrx.com/brimonidine/what-is
  69. https://www.goodrx.com/mirvaso/what-is
  70. https://www.goodrx.com/lumify/what-is
  71. https://glaucomatoday.com/articles/2006-jan-feb/0106_01.html
  72. https://www.drugs.com/availability/generic-alphagan-p.html
  73. https://www.goodrx.com/brimonidine
  74. https://www.pharmacychecker.com/brimonidine/
  75. https://www.drugpatentwatch.com/p/generic/brimonidine%2Btartrate
  76. https://www.volza.com/p/brimonidine/import/
  77. https://onlinelibrary.wiley.com/doi/10.1111/ijd.16717
  78. https://pmc.ncbi.nlm.nih.gov/articles/PMC6776288/
  79. https://apps.tga.gov.au/Prod/msi/Search/Details/brimonidine%2520tartrate
  80. https://www.hmpgloballearningnetwork.com/site/pln/news/apotex-recalls-brimonidinetimolol-ophthalmic-solution-over-sterility-concerns
  81. https://www.goodrx.com/brimonidine/medicare-coverage
  82. https://www.drugs.com/availability/generic-mirvaso.html
Add your contribution
Related Hubs
User Avatar
No comments yet.